1.Application of Intestinal Organoids in The Study of Intestinal Disease Mechanism
Long-Zheng QIANG ; Hai-Guang MAO ; Meng-Ting WANG ; Li-Li QI ; Jin-Bo WANG
Progress in Biochemistry and Biophysics 2024;51(2):394-403
Intestinal organoids are constructed by crypts or stem cells from the intestine under the 3D support of the culture matrix. They contain all mature cells of the intestine, and have become a new and efficient platform for studying the mechanism of intestinal diseases. Compared with 2D cell culture, organoids can not only more effectively simulate the physiological structure and function of the intestine, but also better restore the true ecology of the intestine in different external environments. Therefore, it is more widely used in the study of pathogenesis of different intestinal diseases. This article reviewed the new progress of intestinal organoids culture, and the application and progress of intestinal organoids in the pathogenesis of inflammatory bowel diseases, colorectal cancer and celiac disease in recent years, and also discussed the application of intestinal organoids in drug research and development and screening.
2.Clinical Features and CT Imaging Findings of Melioidosis Pneumonia
Sheng-shi MAI ; Hong-zhang ZHU ; Guang-qiang ZHAO ; Hai CHEN ; Meng ZHANG
Journal of Sun Yat-sen University(Medical Sciences) 2023;44(6):1038-1045
ObjectiveTo summarize and analyze the clinical features and CT imaging findings of melioidosis pneumonia in order to increase awareness of this disease. MethodsA retrospective study was done on clinical and CT imaging data of 68 cases with melioidosis pneumonia diagnosed from January 1, 2012 to April 1, 2023. ResultsOf the 68 cases, 62 presented with acute infection and 6 chronic infection, 88.2% were male, 85.3% were native residents of Hainan, 85.3% were farmers, 77.9% had onset in summer and autumn, 66.2% had diabetes, 100% had fever as the first clinical symptom, and 88.2% were confirmed positive by blood culture. In most patients, white blood cell count, neutrophil ratio, C-reactive protein and calcitonin levels increased, while lymphocyte ratio decreased, but no statistical difference was found between acute and chronic infection groups (P > 0.05). Of the patients, 36.8% recovered, 42.6% got better, 11.8% patients became therapy-resistant and 8.8% died. CT image showed pathomorphological changes including nodules/masses, patchy ground-glass attenuation or large patchy consolidation or all of these at the same time. Acute and chronic infection groups had significant difference in pathomorphological changes (P = 0.01), but no statistical difference in other imaging findings. Moreover, 36.8% of the patients developed extrapulmonary infections, 8.8% of which multi-site abscess formation. ConclusionsMelioidosis Pneumonia should be considered if the patient is the sojourner from epidemic area, or has diabetes, high fever and rapid-developing disease, with additional presence of multiple inflammatory lesions in lung CT.
3.Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial.
Jie WU ; Shu-Wei DUAN ; Hong-Tao YANG ; Yue-Yi DENG ; Wei LI ; Ya-Ni HE ; Zhao-Hui NI ; Yong-Li ZHAN ; Shan LIN ; Zhi-Yong GUO ; Jun ZHU ; Jing-Ai FANG ; Xu-Sheng LIU ; Li-Hua WANG ; Rong WANG ; Nian-Song WANG ; Xiao-Hong CHENG ; Li-Qun HE ; Ping LUO ; Shi-Ren SUN ; Ji-Feng SUN ; Ai-Ping YIN ; Geng-Ru JIANG ; Hong-Yu CHEN ; Wen-Hu LIU ; Hong-Li LIN ; Meng LIANG ; Lu MA ; Ming CHEN ; Li-Qun SONG ; Jian CHEN ; Qing ZHU ; Chang-Ying XING ; Yun LI ; Ji-Ning GAO ; Rong-Shan LI ; Ying LI ; Hao ZHANG ; Ying LU ; Qiao-Ling ZHOU ; Jun-Zhou FU ; Qiang HE ; Guang-Yan CAI ; Xiang-Mei CHEN
Journal of Integrative Medicine 2021;19(2):111-119
BACKGROUND:
Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease.
OBJECTIVE:
This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard drug, losartan potassium.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTION:
This was a multicenter, double-blind, randomized, controlled clinical trial. Primary glomerulonephritis patients, aged 18-70 years, with blood pressure ≤ 140/90 mmHg, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min per 1.73 m
MAIN OUTCOME MEASURES:
The primary outcome was change in the 24-hour proteinuria level, after 48 weeks of treatment.
RESULTS:
A total of 735 participants were enrolled. The percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78% ± 2.56% (P = 0.006) more than that in the losartan 50 mg group, which was 0.51% ± 2.54% (P = 1.000) less than that in the losartan 100 mg group. Compared with the losartan potassium 50 mg group, the SYKFT plus losartan potassium 50 mg group had a 13.39% ± 2.49% (P < 0.001) greater reduction in urine protein level. Compared with the losartan potassium 100 mg group, the SYKFT plus losartan potassium 100 mg group had a 9.77% ± 2.52% (P = 0.001) greater reduction in urine protein. With a superiority threshold of 15%, neither was statistically significant. eGFR, serum creatinine and serum albumin from the baseline did not change statistically significant. The average change in TCM syndrome score between the patients who took SYKFT (-3.00 [-6.00, -2.00]) and who did not take SYKFT (-2.00 [-5.00, 0]) was statistically significant (P = 0.003). No obvious adverse reactions were observed in any group.
CONCLUSION:
SYKFT decreased the proteinuria and improved the TCM syndrome scores of primary glomerulonephritis patients, with no change in the rate of decrease in the eGFR. SYKFT plus losartan potassium therapy decreased proteinuria more than losartan potassium therapy alone.
TRIAL REGISTRATION NUMBER
NCT02063100 on ClinicalTrials.gov.
4.Immunoregulatory Effect of Chaihu Jia Longgu Mulitang Modified with Bupleuri Radix on Hippocampal NLRP3 Pathway in Depressed Rats
Li-zhi SHANG ; Meng-di MAO ; Er-ping XU ; Ming-yuan ZHANG ; Chun-yu ZHOU ; Guo-qiang WANG ; Yao-yang LI ; Bao-guang LIU ; Ming BAI ; Yu-cheng LI ; Bao-ying WANG ; Xiao-hui CHEN
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(24):33-39
Objective:To investigate the effect and mechanism of Chaihu Jia Longgu Mulitang (CJLM) on hippocampal NOD-like receptor protein 3 (NLRP3)inflammasome pathway in rats with depression. Method:Sixty male SD rats were randomly divided into a normal group,a model group, a MCC950 (1 mg·kg-1) group, and high- (13 g·kg-1), medium- (6.5 g·kg-1), and low-dose (3.25 g·kg-1) Chaihu Jia Longgu Mulitang groups, with 10 rats in each group.The depression model was induced by isolation combined with chronic unpredictable mild stimulation(CUMS) in rats except for those in the normal group. Rats were treated correspondingly for 21 days by intraperitoneal injection in the MCC950 group and gavage in other groups. The normal group and the model group received an equal volume of normal saline. The depression-like behaviors of rats were observed by sucrose preference test (SPT) and novelty-suppressed feeding test. Enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of interleukin-1
5.Soil Physical and Chemical Properties, Microorganisms and Metabolites in Different Culture Environments of Gastrodia elata
Pei WANG ; Guang-yun MENG ; Ru-zhi MAO ; Kuan YANG ; Zhao-hui SU ; Zhong-qiao WANG ; Shun-qiang YANG ; Hong-ping HUANG ; Xia-hong HE
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(14):164-174
Objective:To study the soil physical and chemical properties, microorganisms, and metabolites in different culture environments of
6.Effect of Chaihu Jia Longgu Mulitang on Signaling Pathway of PI3K/Akt/GSK3β/β-catenin in Hippocampus Tissue of Rats with Depression
Li-zhi SHANG ; Meng-di MAO ; Er-ping XU ; Guo-qiang WANG ; Yao-yang LI ; Bao-guang LIU ; Ming BAI ; Yu-cheng LI ; Bao-ying WANG
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(23):12-19
Objective:To study the effect of Chaihu Jia Longgu Mulitang on phosphatidylinositol-3-kinases (PI3K)/protein kinase B (Akt)/glycogen synthase kinase 3
7.Effect of Modified Xiao Chaihutang on Expression of EAATs and VGLUTs in Hippocampus of Chronic Restraibt Stress Depression Model Rat
Er-ping XU ; Meng-di MAO ; Li-zhi SHANG ; Guo-qiang WANG ; Bao-guang LIU ; Yao-yang LI ; Ming BAI ; Yu-cheng LI ; Bao-ying WANG ; Xiao-hui CHEN
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(23):27-36
Objective:To study the effect of modified Xiao Chaihutang on the expressions of excitatory amino acid transporters(EAATs) and vesicle glutamate transporters(VGLUTs)in hippocampus of rats with chronic depression, in order to explore the anti-depressant mechanism of modified Xiao Chaihutang based on glutamate transport. Method:A total of 120 SD rats were randomly divided into normal group, model group, and low, middle and high-dose modified Xiaochaihutang groups (6.5, 13, 26 g·kg-1) and riluzole group, with 20 rats in each group.Except normal group, the depression model of rats was prepared through Chronic restraint stress(CRS). The normal group and the model group were intragastrically (
8.Regulatory Effect of Modified Erchentang on Levels of Lymphokines Relating to Th1,Th2 and Th9 Cells and Expressions of IL-4R1/IL-13RA1 in Bronchioles of Rats with Chronic Obstructive Pulmonary Disease
Meng-di MAO ; Li-zhi SHANG ; Li-li XU ; Shu JI ; Long-tao SHI ; Yao-yang LI ; Guang-yuan ZHANG ; Guo-qiang WANG ; Wen-ying XIE
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(20):16-24
Objective:To study the effect of modified Erchentang on levels of interleukin-12 (IL-12), interferon-
9.Mechanism of Modified Erchentang on Expression of CXCL8-CXCR1/2 Axle Genes in Lung Tissue of Rats with Chronic Obstructive Pulmonary Disease
Li-zhi SHANG ; Shu JI ; Long-tao SHI ; Yao-yang LI ; Meng-di MAO ; Guang-yuan ZHANG ; Guo-qiang WANG ; Wen-ying XIE ; Li-li XU
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(11):40-48
Objective:To observe the effect of modified Erchentang on the expression of CXC chemokine ligand (CXCL) 8-CXC chemotaxis factor receptor (CXCR) 1/2 genes in the lung tissue of rats with chronic obstructive pulmonary disease (COPD)
10.Establishment of Secondary HLH Mouse Model and Effect of Ruxolitinib on Disease Manifestations of Model Mide.
Guang-Qiang MENG ; Jing-Shi WANG ; Wen-Yuan LAI ; Yue SONG ; Zhuo GAO ; Shuo MENG ; Jia ZHANG ; Yi-Ni WANG ; Zhao WANG
Journal of Experimental Hematology 2020;28(4):1376-1380
OBJECTIVE:
To establish a secondary hemophagocytic lymphohistiocytosis(HLH) mouse model, and to investigate the effect of ruxolitinib on the disease manifestation of model mice.
METHODS:
Wild type C57BL/6 mice were randomly divided into 4 groups: two groups of mice were intraperitoneally injected with CpG oligodeoxynucleotide 1826 (CpG-ODN1826) every other day to induce HLH, and other two groups were control groups. One group of the CpG-ODN1826 groups and one of the control groups were given ruxolitinib, and other two groups were given the same amount of PBS. Blood samples, serum ferritin and hepatic/spleen weights of experimental mice were detected and serum cytokine levels were measured by ELISA.
RESULTS:
Compared with the control groups, the levels of white blood cells, hemoglobin and platelets in the CpG-ODN1826 groups were significantly lower (P<0.05); and liver/body weight, spleen/body weight, serum ferritin, sCD25, IL-10, IL-1β, IFN-Ƴ, IL-12p70, GM-CSF, TNF-α and IL-18 levels significantly increased (P<0.05). There was no significant difference in the levels of IL-2, IL-4, IL-5, IL-6, IL-22, IL-13, IL-27 and IL-23 between the two groups (P>0.05). The spleen in CpG group had disordered internal structure, expanding red pulp and hyperplastic nucleated cells. The liver had severe perivascular inflammations. The spleen/weight of the ruxolitinib-treated mice in the CpG-ODN1826 group was significantly smaller than that of the unapplied ruxolitinib (P<0.05).
CONCLUSION
The CpG-ODN1826 can induce secondary HLH symptoms in wild type C57BL/6 mice. Ruxolitinib can alleviate the symptoms of splenomegaly in HLH model mice.
Animals
;
Disease Models, Animal
;
Lymphohistiocytosis, Hemophagocytic
;
Mice
;
Mice, Inbred C57BL
;
Pyrazoles

Result Analysis
Print
Save
E-mail